Skip to content
2000
Volume 18, Issue 3
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Escalating resistance to almost every class of antibiotics is reducing the utility of currently available antimicrobial drugs. A part of this menace is attributed to poor pharmacokinetics and pharmacodynamics of the drug. Improvement in drug delivery is the most challenging task encountered by the pharmaceutical industries; however nanotechnology can bring a revolution in drug delivery design. Nano-antimicrobials (NAMs) have their own intrinsic antimicrobial activity (nanoparticles) or augment overall efficacy of enclosed antibiotics (nano-carriers), thus contribute in mitigating or reversing the resistance phenomenon. Nano-particles (NPs) having their own intrinsic antimicrobial activity kill microbes by mimicking natural course of killing by phagocytic cells i.e., by producing large quantity of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). It is believed that NPs kill microbes by simultaneously acting on many essential life processes or metabolic routes of microbes; that as many genetic mutations to develop resistance against them seems to be impossible. Nano carriers improve the pharmacokinetics of the enclosed drug. Moreover, one of the major techniques by which NAMs can overcome resistance is targeted drug delivery to the site of disease. In this review, a comprehensive detail about the mechanism of action of NAMs are presented in context to multi drug resistance phenomenon.

Loading

Article metrics loading...

/content/journals/cdt/10.2174/1389450116666151019101826
2017-03-01
2025-05-04
Loading full text...

Full text loading...

/content/journals/cdt/10.2174/1389450116666151019101826
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test